about
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacyThe TRPA1 channel in migraine mechanism and treatmentStructural characterization and kinetics of nitric-oxide synthase inhibition by novel N5-(iminoalkyl)- and N5-(iminoalkenyl)-ornithinesIncreased pulsatile cerebral blood flow, cerebral vasodilation, and postsyncopal headache in adolescents.Role of the immune system in chronic pain.Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches.Alcohol and migraine: trigger factor, consumption, mechanisms. A review.Peripheral and central mechanisms in tension-type headache: an update.Etiology of primary headaches: the importance of genes and environment.Can we develop neurally acting drugs for the treatment of migraine?Migraine: emerging treatment options for preventive and acute attack therapy.Localization of soluble guanylyl cyclase in the superficial dorsal horn.Vascular actions of estrogens: functional implications.Pearls and pitfalls in genetic studies of migraine.TRPA1 and other TRP channels in migraine.Emerging drugs for migraine treatment.Inhibition of nitric oxide synthesis in mouse macrophage cells by feverfew supercritical extract.Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-alpha and matrix metalloproteinase-9 in an animal model of migraine.Interferon treatment may trigger primary headaches in multiple sclerosis patients.Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.Cortical spreading depression and gene regulation: relevance to migraine.Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies.Nitric oxide pathway and response to nitroglycerin in cluster headache patients: plasma nitrite and citrulline levels.Periods of cluster headache induced by nitrate therapy and spontaneous remission of angina pectoris during active clusters.Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs.Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.Increase in NADPH-diaphorase-positive and neuronal NO synthase immunoreactive neurons in the rat spinal trigeminal nucleus following infusion of a NO donor--evidence for a feed-forward process in NO production involved in trigeminal nociception.Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant.A naturalistic glyceryl trinitrate infusion migraine model in the rat.Interaction of calcitonin gene-related peptide, nitric oxide and histamine release in neurogenic blood flow and afferent activation in the rat cranial dura mater.The headache-inducing effect of cilostazol in human volunteers.Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteersNitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activationHeadache Induced by Accidental Nitric Acid InhalationNitric oxide synthase, Calcitonin Gene-Related Peptide and inflammatory mechanisms are involved in GTN induced neuronal activation
P2860
Q24321991-C9CE47C9-3F3C-4170-B224-2FA802ED230CQ27016641-1E1FAB7A-2666-4186-9A47-B13ED3AD43CAQ27641968-975A83D6-35B2-4D7F-8E11-5DF4E8EE6B2FQ33160052-481404B4-42FC-4FF5-B51A-9785A88FEAB8Q34431134-A2BBED20-5912-42F6-92A5-251718CCC265Q34544624-B7837D32-376E-4110-BC7B-BE4388A46B9CQ34743274-A791EDD2-7EBE-4DA9-A007-68BC153AB679Q35109152-2D0C7F49-9C02-447D-9749-EC5A14080339Q36106980-6956F648-494B-4449-835A-06ADCD61224EQ36240187-64A5511B-6B73-4F0F-8509-34E74DEFDDB4Q36580576-1A6F6603-868C-450D-A09A-C817103F29BDQ37001830-18452259-AF46-4606-A3EB-8D15C67C27F2Q37088243-53F4A30A-2B69-4F08-9B8B-6CD85FE470A0Q38106687-B7D659E7-0B5D-468A-8DD1-C9F7A3FB0F58Q38128581-51685987-245E-452B-A8F0-589DE2738ED4Q38303376-CCA04A21-453F-4CBA-9129-6D285F3B3474Q39471974-77C67814-9E0B-4C94-ADF5-B1D98AC4A37AQ40055168-30375367-322B-47DB-90CA-C79993B0B9E0Q42594989-C9876DD0-603C-444E-8153-9EFCA1FD682FQ42613452-F9A4009B-5D40-4DE7-8E9F-03EFA4EB93DAQ42632012-88E42699-0F59-4EAB-B393-B545C580CE83Q43938462-B8D899C3-E953-4D90-B3F3-4A4506328ADEQ44375737-2A481A52-36D3-4B0D-951F-50572E611D53Q44478616-E26EF45F-1F50-4EC0-BB92-5223D5CFC04AQ44731904-0AE19471-6408-467B-881D-0D37C35D9A11Q45926654-9EF8F806-B8F5-4220-94C7-52FD810E340EQ46119680-2DDD303F-AE85-4006-B37C-0323EEE05FA6Q46120634-E84055EE-C61F-4B4B-82E7-5F35D22F4A4EQ46761733-996779EB-015E-4FF6-8F5C-92099AB4A523Q47846919-FC9201E1-064E-4851-91E7-D4A90B219587Q48203161-73675FDC-62DC-47FC-A5BD-604235F9BC73Q51023020-80053009-C9F3-47D4-90C3-EC0E0B696E4EQ53515405-4C22A262-4150-418C-99CA-5ABB6F77BCFCQ57023753-5810A9E3-1544-4054-A899-D58B93AE2BA7Q57023856-4F664946-6D60-451B-BBD9-91EBF94BC987Q58769160-B63F6C7A-BC3B-4C3D-B244-7353D64D7970Q59294054-519BE79A-46E5-4B0E-9252-24927EBDCADB
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Nitric oxide in primary headaches.
@ast
Nitric oxide in primary headaches.
@en
Nitric oxide in primary headaches.
@nl
type
label
Nitric oxide in primary headaches.
@ast
Nitric oxide in primary headaches.
@en
Nitric oxide in primary headaches.
@nl
prefLabel
Nitric oxide in primary headaches.
@ast
Nitric oxide in primary headaches.
@en
Nitric oxide in primary headaches.
@nl
P1476
Nitric oxide in primary headaches.
@en
P2093
P304
P356
10.1097/00019052-200106000-00009
P577
2001-06-01T00:00:00Z